Inhibition of the rise in FFA by Acipimox partially prevents GH-induced insulin resistance in GH-deficient adults
(2001) In Journal of Clinical Endocrinology and Metabolism 86(12). p.5813-5818- Abstract
- To test the hypothesis that GH-induced insulin resistance is mediated by an increase in FFA levels we assessed insulin sensitivity after inhibiting the increase in FFA by a nicotine acid derivative, Acipimox, in nine GH-deficient adults receiving GH replacement therapy. The patients received in a double blind fashion either Acipimox (500 mg) or placebo before a 2-h euglycemic (plasma glucose, 5.5 +/- 0.2 mmol/liter) hyperinsulinemic (serum insulin, 28.7 +/- 6.3 mU/liter) clamp in combination with indirect calorimetry and infusion of [3-(3)H]glucose. Acipimox decreased fasting FFA by 88% (P = 0.012) and basal lipid oxidation by 39% (P = 0.015) compared with placebo. In addition, the insulin-stimulated lipid oxidation was 31% (P = 0.0077)... (More)
- To test the hypothesis that GH-induced insulin resistance is mediated by an increase in FFA levels we assessed insulin sensitivity after inhibiting the increase in FFA by a nicotine acid derivative, Acipimox, in nine GH-deficient adults receiving GH replacement therapy. The patients received in a double blind fashion either Acipimox (500 mg) or placebo before a 2-h euglycemic (plasma glucose, 5.5 +/- 0.2 mmol/liter) hyperinsulinemic (serum insulin, 28.7 +/- 6.3 mU/liter) clamp in combination with indirect calorimetry and infusion of [3-(3)H]glucose. Acipimox decreased fasting FFA by 88% (P = 0.012) and basal lipid oxidation by 39% (P = 0.015) compared with placebo. In addition, the insulin-stimulated lipid oxidation was 31% (P = 0.0077) lower during Acipimox than during placebo. Acipimox increased insulin-stimulated total glucose uptake by 36% (P = 0.021) compared with placebo, which mainly was due to a 47% (P = 0.015) increase in glucose oxidation. GH induced insulin resistance is partially prevented by inhibition of lipolysis by Acipimox. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1122512
- author
- Segerlantz, Mikael LU ; Bramnert, Margareta LU ; Manhem, Per ; Laurila, Esa LU and Groop, Leif LU
- publishing date
- 2001
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Clinical Endocrinology and Metabolism
- volume
- 86
- issue
- 12
- pages
- 5813 - 5818
- publisher
- Oxford University Press
- external identifiers
-
- pmid:11739444
- scopus:0035218344
- ISSN
- 1945-7197
- DOI
- 10.1210/jc.86.12.5813
- language
- English
- LU publication?
- no
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Pediatrics/Urology/Gynecology/Endocrinology (013240400), Diabetes and Endocrinology (013241530)
- id
- 98bddba0-69ae-470f-9834-ba355e1ac44d (old id 1122512)
- date added to LUP
- 2016-04-01 16:45:22
- date last changed
- 2022-01-28 21:55:52
@article{98bddba0-69ae-470f-9834-ba355e1ac44d, abstract = {{To test the hypothesis that GH-induced insulin resistance is mediated by an increase in FFA levels we assessed insulin sensitivity after inhibiting the increase in FFA by a nicotine acid derivative, Acipimox, in nine GH-deficient adults receiving GH replacement therapy. The patients received in a double blind fashion either Acipimox (500 mg) or placebo before a 2-h euglycemic (plasma glucose, 5.5 +/- 0.2 mmol/liter) hyperinsulinemic (serum insulin, 28.7 +/- 6.3 mU/liter) clamp in combination with indirect calorimetry and infusion of [3-(3)H]glucose. Acipimox decreased fasting FFA by 88% (P = 0.012) and basal lipid oxidation by 39% (P = 0.015) compared with placebo. In addition, the insulin-stimulated lipid oxidation was 31% (P = 0.0077) lower during Acipimox than during placebo. Acipimox increased insulin-stimulated total glucose uptake by 36% (P = 0.021) compared with placebo, which mainly was due to a 47% (P = 0.015) increase in glucose oxidation. GH induced insulin resistance is partially prevented by inhibition of lipolysis by Acipimox.}}, author = {{Segerlantz, Mikael and Bramnert, Margareta and Manhem, Per and Laurila, Esa and Groop, Leif}}, issn = {{1945-7197}}, language = {{eng}}, number = {{12}}, pages = {{5813--5818}}, publisher = {{Oxford University Press}}, series = {{Journal of Clinical Endocrinology and Metabolism}}, title = {{Inhibition of the rise in FFA by Acipimox partially prevents GH-induced insulin resistance in GH-deficient adults}}, url = {{http://dx.doi.org/10.1210/jc.86.12.5813}}, doi = {{10.1210/jc.86.12.5813}}, volume = {{86}}, year = {{2001}}, }